Contact Information

Call us at: (614)722-2678

Fax us at: (614)722-3273

Center for Gene TherapyAbigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Learn more about Paul T. Martin

Biography

Paul T. Martin, PhD, is a Principal Investigator in the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital. He is Professor of Pediatrics and Professor of Physiology and Cell Biology at The Ohio State University College of Medicine. He is also Associate Director of the NIH Center of Research Translation in Muscular Dystrophy Therapeutic Develpment at Nationwide Children’s Hospital. Dr. Martin’s NIH-funded research program focuses on defining functional roles for cell surface carbohydrates in neuromuscular development and disease. Dr. Martin’s lab has identified particular carbohydrates that, when overexpressed in muscle cells, can prevent muscular dystrophy from occurring in a number of forms of the disease. Current work is focused on translating these findings into therapies that can be used by patients with these disorders. Additional work focuses on on the development of novel protein and gene therapies for congenital forms of muscular dystrophy.

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Neurology

Principal Investigator

Neuromuscular Disorders

Principal Investigator

Primary Department

Center for Gene Therapy

Research

Lab(s)

Center for Gene Therapy

The Martin lab focuses on two main research areas: 1. Development of novel gene therapies for neuromuscular disorders and 2. Identification of functional roles for glycans in muscle and neuromuscular biology.  A major current focus of the lab is on translational research using the GALGT2 gene as a surrogate gene therapy for Duchenne Muscular Dystrophy.  The lab has shown that overexpression of GALGT2 can inhibit the development of muscular dystrophy in a number of disease models and is currently involved in a phase 1 clinical trial of GALGT2 gene therapy in DMD patients.   Other translational gene therapy projects involve the design and testing of new treatments for congenital and limb girdle forms of muscular dystrophy as well as for congenital myasthenias. 

Professional Experience

2009 - Present Department of Pediatrics, The Research Institute at Nationwide Children’s Hospital, and The Ohio State University, Professor of Pediatrics2005 - Present Departmet of Pediatrics, The Research Institute at Nationwide Children’s Hospital and The Ohio State University, Associate Professor of Pediatrics2004 - Present Center for Gene Therapy The Research Institute at Nationwide Children’s Hospital, Principal Investigator2004 - Present Center for Gene Therapy The Research Institute at Nationwide Children’s Hospital, Principal Investigator2005 - 2009 Department of Pediatrics, The Research Institute at Nationwide Children’s Hospital, and The Ohio State University, Associate Professor of Pediatrics2004 - 2004 Department of Neuroscience, University of California, Associate Professor2004 - 2004 Department of Neuroscience, University of California, Associate Professor1996 - 2004 Department of Neurosciences, University of California, Assistant Professor

Contact Information

Center for Gene Therapy

Call us at: (614)722-2678

Fax us at: (614)722-3273

                    Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Contact Information

Call us at: (614)722-2678

Fax us at: (614)722-3273

Center for Gene TherapyAbigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Learn more about Paul T. Martin

Biography

Paul T. Martin, PhD, is a Principal Investigator in the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital. He is Professor of Pediatrics and Professor of Physiology and Cell Biology at The Ohio State University College of Medicine. He is also Associate Director of the NIH Center of Research Translation in Muscular Dystrophy Therapeutic Develpment at Nationwide Children’s Hospital. Dr. Martin’s NIH-funded research program focuses on defining functional roles for cell surface carbohydrates in neuromuscular development and disease. Dr. Martin’s lab has identified particular carbohydrates that, when overexpressed in muscle cells, can prevent muscular dystrophy from occurring in a number of forms of the disease. Current work is focused on translating these findings into therapies that can be used by patients with these disorders. Additional work focuses on on the development of novel protein and gene therapies for congenital forms of muscular dystrophy.

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Neurology

Principal Investigator

Neuromuscular Disorders

Principal Investigator

Primary Department

Center for Gene Therapy

Research

Lab(s)

Center for Gene Therapy

The Martin lab focuses on two main research areas: 1. Development of novel gene therapies for neuromuscular disorders and 2. Identification of functional roles for glycans in muscle and neuromuscular biology.  A major current focus of the lab is on translational research using the GALGT2 gene as a surrogate gene therapy for Duchenne Muscular Dystrophy.  The lab has shown that overexpression of GALGT2 can inhibit the development of muscular dystrophy in a number of disease models and is currently involved in a phase 1 clinical trial of GALGT2 gene therapy in DMD patients.   Other translational gene therapy projects involve the design and testing of new treatments for congenital and limb girdle forms of muscular dystrophy as well as for congenital myasthenias. 

Professional Experience

2009 - Present Department of Pediatrics, The Research Institute at Nationwide Children’s Hospital, and The Ohio State University, Professor of Pediatrics2005 - Present Departmet of Pediatrics, The Research Institute at Nationwide Children’s Hospital and The Ohio State University, Associate Professor of Pediatrics2004 - Present Center for Gene Therapy The Research Institute at Nationwide Children’s Hospital, Principal Investigator2004 - Present Center for Gene Therapy The Research Institute at Nationwide Children’s Hospital, Principal Investigator2005 - 2009 Department of Pediatrics, The Research Institute at Nationwide Children’s Hospital, and The Ohio State University, Associate Professor of Pediatrics2004 - 2004 Department of Neuroscience, University of California, Associate Professor2004 - 2004 Department of Neuroscience, University of California, Associate Professor1996 - 2004 Department of Neurosciences, University of California, Assistant Professor

Contact Information

Center for Gene Therapy

Call us at: (614)722-2678

Fax us at: (614)722-3273

                    Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Contact Information

Call us at: (614)722-2678

Fax us at: (614)722-3273

Center for Gene TherapyAbigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Learn more about Paul T. Martin

Contact Information

  • Call us at:
  • (614)722-2678
  • Fax us at:
  • (614)722-3273
  • Center for Gene TherapyAbigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Learn more about Paul T. Martin

Biography

Paul T. Martin, PhD, is a Principal Investigator in the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital. He is Professor of Pediatrics and Professor of Physiology and Cell Biology at The Ohio State University College of Medicine. He is also Associate Director of the NIH Center of Research Translation in Muscular Dystrophy Therapeutic Develpment at Nationwide Children’s Hospital. Dr. Martin’s NIH-funded research program focuses on defining functional roles for cell surface carbohydrates in neuromuscular development and disease. Dr. Martin’s lab has identified particular carbohydrates that, when overexpressed in muscle cells, can prevent muscular dystrophy from occurring in a number of forms of the disease. Current work is focused on translating these findings into therapies that can be used by patients with these disorders. Additional work focuses on on the development of novel protein and gene therapies for congenital forms of muscular dystrophy.

Biography

Paul T. Martin, PhD, is a Principal Investigator in the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital. He is Professor of Pediatrics and Professor of Physiology and Cell Biology at The Ohio State University College of Medicine. He is also Associate Director of the NIH Center of Research Translation in Muscular Dystrophy Therapeutic Develpment at Nationwide Children’s Hospital. Dr. Martin’s NIH-funded research program focuses on defining functional roles for cell surface carbohydrates in neuromuscular development and disease. Dr. Martin’s lab has identified particular carbohydrates that, when overexpressed in muscle cells, can prevent muscular dystrophy from occurring in a number of forms of the disease. Current work is focused on translating these findings into therapies that can be used by patients with these disorders. Additional work focuses on on the development of novel protein and gene therapies for congenital forms of muscular dystrophy.

Biography

Paul T. Martin, PhD, is a Principal Investigator in the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital. He is Professor of Pediatrics and Professor of Physiology and Cell Biology at The Ohio State University College of Medicine. He is also Associate Director of the NIH Center of Research Translation in Muscular Dystrophy Therapeutic Develpment at Nationwide Children’s Hospital. Dr. Martin’s NIH-funded research program focuses on defining functional roles for cell surface carbohydrates in neuromuscular development and disease. Dr. Martin’s lab has identified particular carbohydrates that, when overexpressed in muscle cells, can prevent muscular dystrophy from occurring in a number of forms of the disease. Current work is focused on translating these findings into therapies that can be used by patients with these disorders. Additional work focuses on on the development of novel protein and gene therapies for congenital forms of muscular dystrophy.

Paul T. Martin, PhD, is a Principal Investigator in the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital. He is Professor of Pediatrics and Professor of Physiology and Cell Biology at The Ohio State University College of Medicine. He is also Associate Director of the NIH Center of Research Translation in Muscular Dystrophy Therapeutic Develpment at Nationwide Children’s Hospital. Dr. Martin’s NIH-funded research program focuses on defining functional roles for cell surface carbohydrates in neuromuscular development and disease. Dr. Martin’s lab has identified particular carbohydrates that, when overexpressed in muscle cells, can prevent muscular dystrophy from occurring in a number of forms of the disease. Current work is focused on translating these findings into therapies that can be used by patients with these disorders. Additional work focuses on on the development of novel protein and gene therapies for congenital forms of muscular dystrophy.

Paul T. Martin, PhD, is a Principal Investigator in the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital. He is Professor of Pediatrics and Professor of Physiology and Cell Biology at The Ohio State University College of Medicine. He is also Associate Director of the NIH Center of Research Translation in Muscular Dystrophy Therapeutic Develpment at Nationwide Children’s Hospital. Dr. Martin’s NIH-funded research program focuses on defining functional roles for cell surface carbohydrates in neuromuscular development and disease. Dr. Martin’s lab has identified particular carbohydrates that, when overexpressed in muscle cells, can prevent muscular dystrophy from occurring in a number of forms of the disease. Current work is focused on translating these findings into therapies that can be used by patients with these disorders. Additional work focuses on on the development of novel protein and gene therapies for congenital forms of muscular dystrophy.

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Neurology

Principal Investigator

Neuromuscular Disorders

Principal Investigator

Primary Department

Center for Gene Therapy

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Neurology

Principal Investigator

Neuromuscular Disorders

Principal Investigator

Primary Department

Center for Gene Therapy

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Neurology

Principal Investigator

Neuromuscular Disorders

Principal Investigator

Primary Department

Center for Gene Therapy

Center for Gene Therapy

Principal Investigator

Neurology

Principal Investigator

Neuromuscular Disorders

Principal Investigator

Primary Department

Center for Gene Therapy

  • Center for Gene Therapy
  • Principal Investigator
  • Neurology
  • Principal Investigator
  • Neuromuscular Disorders
  • Principal Investigator
  • Primary Department
  • Center for Gene Therapy

Research

Lab(s)

Center for Gene Therapy

The Martin lab focuses on two main research areas: 1. Development of novel gene therapies for neuromuscular disorders and 2. Identification of functional roles for glycans in muscle and neuromuscular biology.  A major current focus of the lab is on translational research using the GALGT2 gene as a surrogate gene therapy for Duchenne Muscular Dystrophy.  The lab has shown that overexpression of GALGT2 can inhibit the development of muscular dystrophy in a number of disease models and is currently involved in a phase 1 clinical trial of GALGT2 gene therapy in DMD patients.   Other translational gene therapy projects involve the design and testing of new treatments for congenital and limb girdle forms of muscular dystrophy as well as for congenital myasthenias. 

Research

Lab(s)

Center for Gene Therapy

The Martin lab focuses on two main research areas: 1. Development of novel gene therapies for neuromuscular disorders and 2. Identification of functional roles for glycans in muscle and neuromuscular biology.  A major current focus of the lab is on translational research using the GALGT2 gene as a surrogate gene therapy for Duchenne Muscular Dystrophy.  The lab has shown that overexpression of GALGT2 can inhibit the development of muscular dystrophy in a number of disease models and is currently involved in a phase 1 clinical trial of GALGT2 gene therapy in DMD patients.   Other translational gene therapy projects involve the design and testing of new treatments for congenital and limb girdle forms of muscular dystrophy as well as for congenital myasthenias. 

Research

Lab(s)

Center for Gene Therapy

The Martin lab focuses on two main research areas: 1. Development of novel gene therapies for neuromuscular disorders and 2. Identification of functional roles for glycans in muscle and neuromuscular biology.  A major current focus of the lab is on translational research using the GALGT2 gene as a surrogate gene therapy for Duchenne Muscular Dystrophy.  The lab has shown that overexpression of GALGT2 can inhibit the development of muscular dystrophy in a number of disease models and is currently involved in a phase 1 clinical trial of GALGT2 gene therapy in DMD patients.   Other translational gene therapy projects involve the design and testing of new treatments for congenital and limb girdle forms of muscular dystrophy as well as for congenital myasthenias. 

Lab(s)

Center for Gene Therapy

The Martin lab focuses on two main research areas: 1. Development of novel gene therapies for neuromuscular disorders and 2. Identification of functional roles for glycans in muscle and neuromuscular biology.  A major current focus of the lab is on translational research using the GALGT2 gene as a surrogate gene therapy for Duchenne Muscular Dystrophy.  The lab has shown that overexpression of GALGT2 can inhibit the development of muscular dystrophy in a number of disease models and is currently involved in a phase 1 clinical trial of GALGT2 gene therapy in DMD patients.   Other translational gene therapy projects involve the design and testing of new treatments for congenital and limb girdle forms of muscular dystrophy as well as for congenital myasthenias. 

Lab(s)

Center for Gene Therapy

The Martin lab focuses on two main research areas: 1. Development of novel gene therapies for neuromuscular disorders and 2. Identification of functional roles for glycans in muscle and neuromuscular biology.  A major current focus of the lab is on translational research using the GALGT2 gene as a surrogate gene therapy for Duchenne Muscular Dystrophy.  The lab has shown that overexpression of GALGT2 can inhibit the development of muscular dystrophy in a number of disease models and is currently involved in a phase 1 clinical trial of GALGT2 gene therapy in DMD patients.   Other translational gene therapy projects involve the design and testing of new treatments for congenital and limb girdle forms of muscular dystrophy as well as for congenital myasthenias. 

Lab(s)

Center for Gene Therapy

  • Center for Gene Therapy

Professional Experience

2009 - Present Department of Pediatrics, The Research Institute at Nationwide Children’s Hospital, and The Ohio State University, Professor of Pediatrics2005 - Present Departmet of Pediatrics, The Research Institute at Nationwide Children’s Hospital and The Ohio State University, Associate Professor of Pediatrics2004 - Present Center for Gene Therapy The Research Institute at Nationwide Children’s Hospital, Principal Investigator2004 - Present Center for Gene Therapy The Research Institute at Nationwide Children’s Hospital, Principal Investigator2005 - 2009 Department of Pediatrics, The Research Institute at Nationwide Children’s Hospital, and The Ohio State University, Associate Professor of Pediatrics2004 - 2004 Department of Neuroscience, University of California, Associate Professor2004 - 2004 Department of Neuroscience, University of California, Associate Professor1996 - 2004 Department of Neurosciences, University of California, Assistant Professor

Professional Experience

2009 - Present Department of Pediatrics, The Research Institute at Nationwide Children’s Hospital, and The Ohio State University, Professor of Pediatrics2005 - Present Departmet of Pediatrics, The Research Institute at Nationwide Children’s Hospital and The Ohio State University, Associate Professor of Pediatrics2004 - Present Center for Gene Therapy The Research Institute at Nationwide Children’s Hospital, Principal Investigator2004 - Present Center for Gene Therapy The Research Institute at Nationwide Children’s Hospital, Principal Investigator2005 - 2009 Department of Pediatrics, The Research Institute at Nationwide Children’s Hospital, and The Ohio State University, Associate Professor of Pediatrics2004 - 2004 Department of Neuroscience, University of California, Associate Professor2004 - 2004 Department of Neuroscience, University of California, Associate Professor1996 - 2004 Department of Neurosciences, University of California, Assistant Professor

Professional Experience

2009 - Present Department of Pediatrics, The Research Institute at Nationwide Children’s Hospital, and The Ohio State University, Professor of Pediatrics2005 - Present Departmet of Pediatrics, The Research Institute at Nationwide Children’s Hospital and The Ohio State University, Associate Professor of Pediatrics2004 - Present Center for Gene Therapy The Research Institute at Nationwide Children’s Hospital, Principal Investigator2004 - Present Center for Gene Therapy The Research Institute at Nationwide Children’s Hospital, Principal Investigator2005 - 2009 Department of Pediatrics, The Research Institute at Nationwide Children’s Hospital, and The Ohio State University, Associate Professor of Pediatrics2004 - 2004 Department of Neuroscience, University of California, Associate Professor2004 - 2004 Department of Neuroscience, University of California, Associate Professor1996 - 2004 Department of Neurosciences, University of California, Assistant Professor

2009 - Present Department of Pediatrics, The Research Institute at Nationwide Children’s Hospital, and The Ohio State University, Professor of Pediatrics2005 - Present Departmet of Pediatrics, The Research Institute at Nationwide Children’s Hospital and The Ohio State University, Associate Professor of Pediatrics2004 - Present Center for Gene Therapy The Research Institute at Nationwide Children’s Hospital, Principal Investigator2004 - Present Center for Gene Therapy The Research Institute at Nationwide Children’s Hospital, Principal Investigator2005 - 2009 Department of Pediatrics, The Research Institute at Nationwide Children’s Hospital, and The Ohio State University, Associate Professor of Pediatrics2004 - 2004 Department of Neuroscience, University of California, Associate Professor2004 - 2004 Department of Neuroscience, University of California, Associate Professor1996 - 2004 Department of Neurosciences, University of California, Assistant Professor

2009 - Present Department of Pediatrics, The Research Institute at Nationwide Children’s Hospital, and The Ohio State University, Professor of Pediatrics

Contact Information

Center for Gene Therapy

Call us at: (614)722-2678

Fax us at: (614)722-3273

                    Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Contact Information

Center for Gene Therapy

Call us at: (614)722-2678

Fax us at: (614)722-3273

                    Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Contact Information

Center for Gene Therapy

Call us at: (614)722-2678

Fax us at: (614)722-3273

                    Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Center for Gene Therapy

Call us at: (614)722-2678

Fax us at: (614)722-3273

                    Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Call us at: (614)722-2678

Fax us at: (614)722-3273

                    Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Call us at: (614)722-2678

Fax us at: (614)722-3273

                    Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)
  • Call us at:
  • (614)722-2678
  • Fax us at:
  • (614)722-3273
  • Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)